Reviewing Ocular Therapeutix Inc. (OCUL)’s and CymaBay Therapeutics Inc. (NASDAQ:CBAY)’s results

This is a contrast between Ocular Therapeutix Inc. (NASDAQ:OCUL) and CymaBay Therapeutics Inc. (NASDAQ:CBAY) based on their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership. The two companies are Biotechnology and they also compete with each other.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ocular Therapeutix Inc. 1.99M 88.04 59.98M -1.59 0.00
CymaBay Therapeutics Inc. N/A 0.00 72.55M -1.04 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Ocular Therapeutix Inc. and CymaBay Therapeutics Inc.

Profitability

Table 2 shows Ocular Therapeutix Inc. and CymaBay Therapeutics Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ocular Therapeutix Inc. -3,014.07% -133.7% -81.6%
CymaBay Therapeutics Inc. 0.00% -27.9% -25.2%

Volatility & Risk

Ocular Therapeutix Inc.’s 1.87 beta indicates that its volatility is 87.00% more volatile than that of S&P 500. CymaBay Therapeutics Inc.’s 1.81 beta is the reason why it is 81.00% more volatile than S&P 500.

Liquidity

The Current Ratio and Quick Ratio of Ocular Therapeutix Inc. are 4.3 and 4.3 respectively. Its competitor CymaBay Therapeutics Inc.’s Current Ratio is 14.8 and its Quick Ratio is 14.8. CymaBay Therapeutics Inc. can pay off short and long-term obligations better than Ocular Therapeutix Inc.

Analyst Recommendations

The Recommendations and Ratings for Ocular Therapeutix Inc. and CymaBay Therapeutics Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ocular Therapeutix Inc. 0 0 5 3.00
CymaBay Therapeutics Inc. 0 1 6 2.86

The consensus target price of Ocular Therapeutix Inc. is $14, with potential upside of 242.30%. Competitively the consensus target price of CymaBay Therapeutics Inc. is $20.43, which is potential 57.15% upside. Based on the analysts opinion we can conclude, Ocular Therapeutix Inc. is looking more favorable than CymaBay Therapeutics Inc.

Institutional & Insider Ownership

Institutional investors held 53.6% of Ocular Therapeutix Inc. shares and 97.5% of CymaBay Therapeutics Inc. shares. Ocular Therapeutix Inc.’s share held by insiders are 0.2%. Competitively, 0.3% are CymaBay Therapeutics Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ocular Therapeutix Inc. -1.26% 24.6% -16.78% -27.43% -14.52% 18.34%
CymaBay Therapeutics Inc. 19.5% 54.25% 46.99% 4.19% -6.28% 70.52%

For the past year Ocular Therapeutix Inc.’s stock price has smaller growth than CymaBay Therapeutics Inc.

Summary

CymaBay Therapeutics Inc. beats on 6 of the 11 factors Ocular Therapeutix Inc.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of ocular therapies using its Hydrogel technology. Its product pipeline candidates utilize its platform to provide differentiated drug delivery solutions that are designed to reduce the complexity and burden of current drop or injection regimens by creating sustained release one-time or several-month dosage forms. The companyÂ’s lead product candidate, DEXTENZA (dexamethasone insert) 0.4 mg for intracanalicular use has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. It is also developing OTX-TP (travoprost insert), which is in Phase 3 clinical development for glaucoma and ocular hypertension. In addition, the company is evaluating injectable drug delivery depots for back-of-the-eye diseases. Further, its commercial product includes the ReSure Sealant, which has been approved by the Food and Drug Administration (FDA) for ophthalmic use. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. It engages in developing seladelpar (MBX-8025), a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes. CymaBay Therapeutics Inc. has licensing agreement with Kowa Pharmaceuticals America, Inc. for the development and commercialization of arhalofenate in the United States; development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products containing halofenate, its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics Inc. was incorporated in 1988 and is headquartered in Newark, California.